Targeting menin for precision therapy in high-risk acute myeloid leukemia

Objective: This mini-review provides an overview of the current evidence for Revumenib, a first-in-class menin inhibitor, in treating AML with KMT2A rearrangements or NPM1 mutations. This therapy represents a promising advancement by selectively disrupting leukemogenic pathways. Summary: The clinica...

Full description

Bibliographic Details
Published in:Leukemia Research Reports
Main Authors: Abdur Jamil, Zaheer Qureshi, Zain Mary El-amir, Gillian Kupakuwana-Suk, Hamzah Akram, Mohsin Ahmad, Eric Huselton
Format: Article
Language:English
Published: Elsevier 2025-01-01
Subjects:
Acute myeloid leukemia
Revumenib
KMT2A
Menin inhibition therapy
Online Access:http://www.sciencedirect.com/science/article/pii/S2213048924000852
Description
Summary:Objective: This mini-review provides an overview of the current evidence for Revumenib, a first-in-class menin inhibitor, in treating AML with KMT2A rearrangements or NPM1 mutations. This therapy represents a promising advancement by selectively disrupting leukemogenic pathways. Summary: The clinical promise of Revumenib in genetically defined AML highlights its potential role in shaping the future treatment landscape. This mini-review underscores the need for ongoing trials to define optimal dosing, safety protocols, and combination therapies, with the ultimate goal of establishing Revumenib as a standard of care for high-risk AML subsets.
ISSN:2213-0489

Similar Items